Synonym
CM 29-712; LY79344; LY-79344; LY 79344
IUPAC/Chemical Name
6-Methyl-8 alpha-1-cyanomethylergoline
InChi Key
BTJQCRNUHAXNNH-CZUORRHYSA-N
InChi Code
InChI=1S/C17H19N3/c1-19-8-3-5-13-14-4-2-6-15-17(14)12(10-16(13)19)11-20(15)9-7-18/h2,4,6,11,13,16H,3,5,8-10H2,1H3/t13-,16-/m1/s1
SMILES Code
[H][C@@]1(N(C)CCC[C@@]12[H])CC3=CN(CC#N)C4=C3C2=CC=C4
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
265.36
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Vigouret JM, Bürki HR, Jaton AL, Züger PE, Loew DM. Neurochemical and neuropharmacological investigations with four ergot derivatives: bromocriptine, dihydroergotoxine, CF 25-397 and CM 29-712. Pharmacology. 1978;16 Suppl 1:156-73. doi: 10.1159/000136817. PMID: 565520.
2: Jaton AL, Loew DM, Vigouret JM. A comparison of apomorphine, bromocriptine and Sandoz CM 29-712 (6-methyl-8a-cyanomethyl-ergoline-l) in four different turning models in the rat [proceedings]. Br J Pharmacol. 1978 Mar;62(3):395P. PMID: 565235; PMCID: PMC1668167.
3: Reavill C, Jenner P, Marsden CD. Differentiation of dopamine agonists using drug-induced rotation in rats with unilateral or bilateral 6-hydroxydopamine destruction of ascending dopamine pathways. Biochem Pharmacol. 1983 Mar 1;32(5):865-70. doi: 10.1016/0006-2952(83)90589-0. PMID: 6301501.
4: Beart PM, McDonald D, Cincotta M, de Vries DJ, Gundlach AL. Selectivity of some ergot derivatives for 5-HT1 and 5-HT2 receptors of rat cerebral cortex. Gen Pharmacol. 1986;17(1):57-62. doi: 10.1016/0306-3623(86)90011-x. PMID: 3949149.
5: Schelkunov EL, Andreeva OG, Korovin KF, Ostroumova MN. The functional role of the noradrenergic neurons in the thermoregulatory circuits in mice. J Neural Transm. 1981;50(2-4):113-37. doi: 10.1007/BF01249134. PMID: 6113267.
6: Fuxe K, Ogren SO, Agnati LF, Andersson K, Hall H, Köhler C, Fredholm B. Central monoamine synapses as sites of action for ergot drugs. Adv Biochem Psychopharmacol. 1980;23:41-62. PMID: 6104914.
7: Markstein R. Neurochemical effects of some ergot derivatives: a basis for their antiparkinson actions. J Neural Transm. 1981;51(1-2):39-59. doi: 10.1007/BF01664004. PMID: 6267192.
8: Rinne UK. Dopamine agonists in the treatment of Parkinson's disease. Adv Neurol. 1983;37:141-50. PMID: 6305175.
9: Rinne UK. Dopamine agonists as primary treatment in Parkinson's disease. Adv Neurol. 1987;45:519-23. PMID: 3103394.
